SI-BONE, Inc. (NASDAQ: SIBN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.34 | Insider Own | 6.25% | Shs Outstand | 44.35M | Perf Week | -1.42% |
| Market Cap | 800.06M | Forward P/E | - | EPS next Y | -0.33 | Insider Trans | -7.98% | Shs Float | 43.23M | Perf Month | -5.75% |
| Enterprise Value | 661.06M | PEG | - | EPS next Q | -0.13 | Inst Own | - | Short Float | 13.02% | Perf Quarter | 18.61% |
| Income | -15.00M | P/S | 3.74 | EPS this Y | -16.65% | Inst Trans | - | Short Ratio | 10.29 | Perf Half Y | 40.39% |
| Sales | 214.00M | P/B | 4.40 | EPS next Y | 17.43% | ROA | -5.88% | Short Interest | 5.63M | Perf YTD | -8.52% |
| Book/sh | 4.10 | P/C | 5.48 | EPS next 5Y | - | ROE | -8.23% | 52W High | 21.89 -17.59% | Perf Year | 19.47% |
| Cash/sh | 3.29 | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.88% | 52W Low | 11.48 57.14% | Perf 3Y | -19.21% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 23.77% 22.45% | Gross Margin | 79.53% | Volatility | 3.52% 3.51% | Perf 5Y | -22.94% |
| Dividend TTM | - | EV/Sales | 3.09 | EPS Y/Y TTM | 54.67% | Oper. Margin | -8.31% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.55 | Sales Y/Y TTM | 28.14% | Profit Margin | -6.85% | RSI (14) | 41.17 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.15 | EPS Q/Q | 35.71% | SMA20 | -4.57% | Beta | 0.67 | Target Price | 23.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 14.29% | SMA50 | -1.66% | Rel Volume | 1.04 | Prev Close | 18.54 |
| Employees | 376 | LT Debt/Eq | 0.22 | Earnings | Nov 09 | SMA200 | 10.23% | Avg Volume | 570.79K | Price | 18.04 |
| IPO Date | Oct 17, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 37.53% 1.21% | Net Debt/EBITDA | 5.19 | Volume | 595,338 | Change | -2.70% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-04-26 | Reiterated | UBS | Buy | $24 → $25 |
| Jul-28-26 | Initiated | UBS | Buy | $24 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $24 → $21 |
| Feb-24-26 | Reiterated | Truist Securities | Buy | $23 → $24 |
| Dec-18-25 | Reiterated | Truist Securities | Buy | $20 → $23 |
| Dec-17-25 | Reiterated | Canaccord Genuity | Buy | $27 |
| Dec-16-25 | Reiterated | Needham | Buy | $19 → $27 |
| Dec-02-25 | Reiterated | Morgan Stanley | Overweight | $18 → $23 |
| Oct-15-25 | Reiterated | Truist Securities | Buy | $18 → $20 |
| Aug-11-25 | Reiterated | Cantor Fitzgerald | Overweight | $25 |
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 214 | 201 | 167 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 44 | 41 | 35 | — | — | — | — | — | — | |
| Gross Profit | 171 | 160 | 132 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 170 | 165 | 151 | — | — | — | — | — | — | |
| Research and Development | 17 | 17 | 17 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | — | — | — | — | — | — | |
| Operating Income | -17 | -22 | -35 | — | — | — | — | — | — | |
| Interest Expense | 4 | 5 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 9 | 8 | — | — | — | — | — | — | |
| Net Income Before Taxes | -15 | -19 | -31 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -15 | -19 | -31 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -15 | -19 | -31 | — | — | — | — | — | — | |
| Net Income | -15 | -19 | -31 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.34 | -0.44 | -0.75 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.34 | -0.44 | -0.75 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.34 | -0.44 | -0.75 | — | — | — | — | — | — | |
| EBITDA | -4 | -11 | -23 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.71 | 4.32 | 3.44 | — | — | — | — | — | — | |
| Gross Margin | 79.91 | 79.60 | 79.04 | — | — | — | — | — | — | |
| Operating Margin | -7.94 | -10.95 | -20.96 | — | — | — | — | — | — | |
| Net Margin | -7.01 | -9.45 | -18.56 | — | — | — | — | — | — | |
| Shares Outstanding | 44 | 44 | 41 | — | — | — | — | — | — | |
| Market Capitalization | 794 | 868 | 575 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| DUNN JEFFREY W | Director | Sep 01 '26 | Sale | 18.91 | 20,000 | 378,160 | 16,057 | Sep 03 |
| DUNN JEFFREY W | Director | Sep 01 '26 | Option Exercise | 4.68 | 20,000 | 93,600 | 36,057 | Sep 03 |
| Maheshwari Anshul | Chief Op & Financial Officer | Aug 24 '26 | Sale | 20.11 | 11,636 | 233,971 | 223,284 | Aug 26 |
| FRANCIS LAURA | Chief Executive Officer | Aug 24 '26 | Sale | 20.12 | 25,972 | 522,596 | 291,491 | Aug 26 |
| Maheshwari Anshul | Chief Op & Financial Officer | Aug 21 '26 | Sale | 20.02 | 11,228 | 224,785 | 234,920 | Aug 21 |
| FRANCIS LAURA | Chief Executive Officer | Aug 21 '26 | Sale | 20.02 | 3,923 | 78,538 | 317,463 | Aug 21 |
| FRANCIS LAURA | Chief Executive Officer | Aug 20 '26 | Sale | 19.46 | 51,884 | 1,009,663 | 321,386 | Aug 21 |
| Maheshwari Anshul | Chief Op & Financial Officer | Aug 19 '26 | Sale | 19.55 | 5,747 | 112,354 | 246,148 | Aug 21 |
| FRANCIS LAURA | Chief Executive Officer | Aug 17 '26 | Sale | 18.66 | 14,956 | 279,065 | 490,461 | Aug 18 |
| PISETSKY MICHAEL A. | SVP, Ops & Adm/Chief Legal Ofr | Aug 17 '26 | Sale | 18.63 | 3,725 | 69,411 | 273,650 | Aug 18 |
| Maheshwari Anshul | Chief Financial Officer | Aug 17 '26 | Sale | 18.65 | 4,665 | 87,015 | 251,895 | Aug 18 |
| DUNN JEFFREY W | Director | Aug 03 '26 | Option Exercise | 4.68 | 20,000 | 93,600 | 36,057 | Aug 05 |
| DUNN JEFFREY W | Director | Aug 03 '26 | Sale | 18.46 | 20,000 | 369,214 | 16,057 | Aug 05 |
| PISETSKY MICHAEL A. | SVP, Ops & Adm/Chief Legal Ofr | Jul 02 '26 | Sale | 16.71 | 3,134 | 52,375 | 277,375 | Jul 06 |
| Maheshwari Anshul | Chief Financial Officer | Jul 02 '26 | Sale | 16.77 | 3,317 | 55,627 | 256,560 | Jul 06 |